[HLFG] YoY Annualized Quarter Result on 31-Mar-2018 [#3]

Announcement Date
30-May-2018
Admission Sponsor
-
Sponsor
-
Financial Year
30-Jun-2018
Quarter
31-Mar-2018 [#3]
Profit Trend
QoQ- 1.91%
YoY- 16.44%
View:
Show?
Annualized Quarter Result
31/03/21 31/03/20 31/03/19 31/03/18 31/03/17 31/03/16 31/03/15 CAGR
Revenue 6,263,782 5,104,888 5,248,216 5,374,829 5,015,330 4,449,108 4,362,690 6.20%
PBT 4,024,092 3,254,982 3,554,324 3,610,610 3,095,764 2,368,306 2,990,441 5.06%
Tax -662,306 -570,356 -616,286 -675,450 -596,524 -417,605 -629,489 0.84%
NP 3,361,785 2,684,626 2,938,037 2,935,160 2,499,240 1,950,701 2,360,952 6.06%
-
NP to SH 2,255,850 1,776,481 1,934,209 1,937,536 1,663,961 1,287,197 1,572,657 6.19%
-
Tax Rate 16.46% 17.52% 17.34% 18.71% 19.27% 17.63% 21.05% -
Total Cost 2,901,997 2,420,261 2,310,178 2,439,669 2,516,090 2,498,406 2,001,738 6.37%
-
Net Worth 22,108,885 20,195,879 19,146,717 17,622,136 16,616,044 15,158,698 12,528,185 9.91%
Dividend
31/03/21 31/03/20 31/03/19 31/03/18 31/03/17 31/03/16 31/03/15 CAGR
Div 163,265 196,664 642,045 609,894 581,408 581,408 530,736 -17.82%
Div Payout % 7.24% 11.07% 33.19% 31.48% 34.94% 45.17% 33.75% -
Equity
31/03/21 31/03/20 31/03/19 31/03/18 31/03/17 31/03/16 31/03/15 CAGR
Net Worth 22,108,885 20,195,879 19,146,717 17,622,136 16,616,044 15,158,698 12,528,185 9.91%
NOSH 1,147,516 1,147,516 1,147,516 1,147,516 1,147,516 1,147,516 1,047,507 1.52%
Ratio Analysis
31/03/21 31/03/20 31/03/19 31/03/18 31/03/17 31/03/16 31/03/15 CAGR
NP Margin 53.67% 52.59% 55.98% 54.61% 49.83% 43.84% 54.12% -
ROE 10.20% 8.80% 10.10% 10.99% 10.01% 8.49% 12.55% -
Per Share
31/03/21 31/03/20 31/03/19 31/03/18 31/03/17 31/03/16 31/03/15 CAGR
RPS 552.46 449.93 457.76 470.01 437.06 387.72 416.48 4.81%
EPS 198.93 156.40 168.93 169.47 145.47 118.13 150.13 4.79%
DPS 14.40 17.33 56.00 53.33 50.67 50.67 50.67 -18.90%
NAPS 19.50 17.80 16.70 15.41 14.48 13.21 11.96 8.48%
Adjusted Per Share Value based on latest NOSH - 1,147,516
31/03/21 31/03/20 31/03/19 31/03/18 31/03/17 31/03/16 31/03/15 CAGR
RPS 545.86 444.86 457.35 468.39 437.06 387.72 380.19 6.20%
EPS 196.59 154.81 168.56 168.85 145.47 118.13 137.05 6.19%
DPS 14.23 17.14 55.95 53.15 50.67 50.67 46.25 -17.82%
NAPS 19.2667 17.5996 16.6853 15.3568 14.48 13.21 10.9176 9.91%
Price Multiplier on Financial Quarter End Date
31/03/21 31/03/20 31/03/19 31/03/18 31/03/17 31/03/16 31/03/15 CAGR
Date 31/03/21 31/03/20 29/03/19 30/03/18 31/03/17 31/03/16 31/03/15 -
Price 17.42 13.68 19.18 19.26 15.90 15.52 16.96 -
P/RPS 3.15 3.04 4.19 4.10 3.64 4.00 4.07 -4.17%
P/EPS 8.76 8.74 11.37 11.37 10.97 13.84 11.30 -4.15%
EY 11.42 11.45 8.80 8.80 9.12 7.23 8.85 4.33%
DY 0.83 1.27 2.92 2.77 3.19 3.26 2.99 -19.21%
P/NAPS 0.89 0.77 1.15 1.25 1.10 1.17 1.42 -7.48%
Price Multiplier on Announcement Date
31/03/21 31/03/20 31/03/19 31/03/18 31/03/17 31/03/16 31/03/15 CAGR
Date 27/05/21 29/05/20 28/05/19 30/05/18 29/05/17 24/05/16 26/05/15 -
Price 17.38 13.28 18.92 18.50 16.42 14.92 15.80 -
P/RPS 3.15 2.95 4.13 3.94 3.76 3.85 3.79 -3.03%
P/EPS 8.74 8.48 11.21 10.92 11.32 13.30 10.52 -3.03%
EY 11.45 11.79 8.92 9.16 8.83 7.52 9.50 3.15%
DY 0.83 1.31 2.96 2.88 3.09 3.40 3.21 -20.16%
P/NAPS 0.89 0.75 1.13 1.20 1.13 1.13 1.32 -6.35%

PBT = Profit before Tax, NP = Net Profit, NP to SH = Net Profit Attributable to Shareholder, Div = Dividend, NP Margin = Net Profit Margin, ROE = Return on Equity, NOSH = Number of Shares, RPS = Revenue per Share, EPS = Earning Per Share, DPS = Dividend Per Share, NAPS = Net Asset Per Share, EOQ = End of Quarter, ANN = Announcement, P/RPS = Price/Revenue per Share, P/EPS = Price/Earning per Share, P/NAPS = Price/Net Asset per Share, EY = Earning Yield, DY = Dividend Yield.

NOSH is estimated based on the NP to SH and EPS. Div is an estimated figure based on the DPS and NOSH. Net Worth is an estimated figure based on the NAPS and NOSH.

Div Payout %, NP Margin, ROE, DY, QoQ & YoY figures in Percentage; RPS, EPS & DPS's figures in Cent; and NAPS's figures in Dollar.

All figures in '000 unless specified.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment